Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

PENTA-TAMOXIFEN TABLETS 10 MG

TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG · DIN 02232551 · PENTAPHARM LTD.

Health Canada status: CANCELLED (UNRETURNED ANNUAL)

What is PENTA-TAMOXIFEN TABLETS?

PENTA-TAMOXIFEN TABLETS 10 MG contains TAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02232551, held by PENTAPHARM LTD., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled (unreturned annual), status dated 05-Apr-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What else is PENTA-TAMOXIFEN TABLETS called?

The same molecule, METHOTREXATE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
METOJECT PENLatinCzechia
NORDIMETLatinCzechia
INJEXATELatinCzechia
TREXAN NEOLatinCzechia
TrexjectLatinAustralia
DBL MethotrexateLatinAustralia
INJEXATE AUTOINJEKTORLatinCzechia
MetojectLatinCzechia, Saudi Arabia
FOXIEMOLatinCzechia
ChexateLatinAustralia
MethoblastinLatinAustralia
METHOTREXAT EBEWELatinCzechia
Methotrexate AccordLatinAustralia
METHOTREXATE BIODIMLatinMorocco
Methotrexate EbeweLatinAustralia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02232551
Brand namePENTA-TAMOXIFEN TABLETS
Generic / active ingredientTAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG
ManufacturerPENTAPHARM LTD.
Strength10 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeL01BA01 METHOTREXATE
AHFS class10:00.00
BiosimilarNo
Health Canada statusCANCELLED (UNRETURNED ANNUAL)
Status date05-Apr-2018

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02232551
DIN (unpadded, as printed on some documents)2232551
Brand namePENTA-TAMOXIFEN TABLETS
Active ingredient / INNTAMOXIFEN (TAMOXIFEN CITRATE) : 10 MG
ATC codeL01BA01
ATC anatomical main groupL — Antineoplastic and immunomodulating agents
ATC therapeutic subgroupL01
AHFS class10:00.00
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderPENTAPHARM LTD.

Which pack is which?

Strength on the label10 MG
Dosage formTABLET
RouteORAL

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

Is METHOTREXATE in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for PENTA-TAMOXIFEN TABLETS

What can be used instead?

Other Canadian products sharing ATC code L01BA01 METHOTREXATE. 20 of 51 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
ACH-METHOTREXATE2.5 MGTABLETACCORD HEALTHCARE INCMARKETEDDIN 02509067
APO-METHOTREXATE2.5 MGTABLETAPOTEX INCMARKETEDDIN 02182963
JAMP METHOTREXATE TABLETS10 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02553740
M-METHOTREXATE2.5 MGTABLETMANTRA PHARMA INCMARKETEDDIN 02534916
METHOTREXATE INJECTION BP25 MGSOLUTIONACCORD HEALTHCARE INCMARKETEDDIN 02474891
METHOTREXATE INJECTION BP25 MGSOLUTIONACCORD HEALTHCARE INCMARKETEDDIN 02327236
METHOTREXATE INJECTION BP25 MGSOLUTIONACCORD HEALTHCARE INCMARKETEDDIN 02464365
METHOTREXATE INJECTION BP25 MGSOLUTIONACCORD HEALTHCARE INCMARKETEDDIN 02474735
METHOTREXATE INJECTION USP10 MGSOLUTIONPFIZER CANADA ULCMARKETEDDIN 02182947
METHOTREXATE INJECTION USP25 MGSOLUTIONPFIZER CANADA ULCMARKETEDDIN 02182777

Who else supplies METHOTREXATE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. METHOTREXATE appears in 251 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does METHOTREXATE cost around the world?

METHOTREXATE is listed on 12 national price registers Nexara tracks, across 263 pack listings published on 11 different price bases. What each country publishes is set out below.

MarketWhat that country publishesBrands listedPack listingsAs of
Czechiamax producer price (ex-factory)97703 Sep 2026
Australiaex-manufacturer73608 Sep 2026
Saudi Arabiapublic193301 Sep 2026
United Statesacquisition32703 Sep 2026
Greeceproducer price (ex-factory)232303 Sep 2026
AustriaKVP (Kassenverkaufspreis)222203 Sep 2026
MoroccoPPV (public price)81705 Sep 2026
United Kingdomhospital9931 Aug 2026
Luxembourgreimbursement9905 Sep 2026
South Africasingle exit price7701 Sep 2026
Bahrainretail (max)2201 Sep 2026
United Arab Emiratespublic1131 Aug 2026

Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.

Ask Nexara for a landed Canadian price

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled (unreturned annual) in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02232551. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.